124 related articles for article (PubMed ID: 15161033)
1. Down-regulation of the human tumor antigen mucin by gemcitabine on the pancreatic cancer cell line capan-2.
Dorn DC; Harnack U; Pecher G
Anticancer Res; 2004; 24(2B):821-5. PubMed ID: 15161033
[TBL] [Abstract][Full Text] [Related]
2. Mucin production determines sensitivity to bortezomib and gemcitabine in pancreatic cancer cells.
Wissniowski TT; Meister S; Hahn EG; Kalden JR; Voll R; Ocker M
Int J Oncol; 2012 May; 40(5):1581-9. PubMed ID: 22266985
[TBL] [Abstract][Full Text] [Related]
3. Apicidin sensitizes pancreatic cancer cells to gemcitabine by epigenetically regulating MUC4 expression.
Ansari D; Urey C; Hilmersson KS; Bauden MP; Ek F; Olsson R; Andersson R
Anticancer Res; 2014 Oct; 34(10):5269-76. PubMed ID: 25275019
[TBL] [Abstract][Full Text] [Related]
4. The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family.
Skrypek N; Duchêne B; Hebbar M; Leteurtre E; van Seuningen I; Jonckheere N
Oncogene; 2013 Mar; 32(13):1714-23. PubMed ID: 22580602
[TBL] [Abstract][Full Text] [Related]
5. Calcitriol Reverses Induced Expression of Efflux Proteins and Potentiates Cytotoxic Activity of Gemcitabine in Capan-2 Pancreatic Cancer Cells.
Gilzad-Kohan H; Sani S; Boroujerdi M
J Pharm Pharm Sci; 2017; 20(0):295-304. PubMed ID: 28885916
[TBL] [Abstract][Full Text] [Related]
6. Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines.
Giovannetti E; Mey V; Danesi R; Mosca I; Del Tacca M
Clin Cancer Res; 2004 May; 10(9):2936-43. PubMed ID: 15131028
[TBL] [Abstract][Full Text] [Related]
7. Interdependence of gemcitabine treatment, transporter expression, and resistance in human pancreatic carcinoma cells.
Hagmann W; Jesnowski R; Löhr JM
Neoplasia; 2010 Sep; 12(9):740-7. PubMed ID: 20824050
[TBL] [Abstract][Full Text] [Related]
8. Down-regulation of deoxycytidine kinase enhances acquired resistance to gemcitabine in pancreatic cancer.
Ohhashi S; Ohuchida K; Mizumoto K; Fujita H; Egami T; Yu J; Toma H; Sadatomi S; Nagai E; Tanaka M
Anticancer Res; 2008; 28(4B):2205-12. PubMed ID: 18751396
[TBL] [Abstract][Full Text] [Related]
9. Pancreatic cancer cells surviving gemcitabine treatment express markers of stem cell differentiation and epithelial-mesenchymal transition.
Quint K; Tonigold M; Di Fazio P; Montalbano R; Lingelbach S; Rückert F; Alinger B; Ocker M; Neureiter D
Int J Oncol; 2012 Dec; 41(6):2093-102. PubMed ID: 23026911
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of the antiproliferative activity of gemcitabine by modulation of c-Met pathway in pancreatic cancer.
Avan A; Quint K; Nicolini F; Funel N; Frampton AE; Maftouh M; Pelliccioni S; Schuurhuis GJ; Peters GJ; Giovannetti E
Curr Pharm Des; 2013; 19(5):940-50. PubMed ID: 22973962
[TBL] [Abstract][Full Text] [Related]
11. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
[TBL] [Abstract][Full Text] [Related]
12. TIMP1 down-regulation enhances gemcitabine sensitivity and reverses chemoresistance in pancreatic cancer.
Tan Y; Li X; Tian Z; Chen S; Zou J; Lian G; Chen S; Huang K; Chen Y
Biochem Pharmacol; 2021 Jul; 189():114085. PubMed ID: 32522594
[TBL] [Abstract][Full Text] [Related]
13. Effect of Gemcitabine based chemotherapy on the immunogenicity of pancreatic tumour cells and T-cells.
Smith PL; Yogaratnam Y; Samad M; Kasow S; Dalgleish AG
Clin Transl Oncol; 2021 Jan; 23(1):110-121. PubMed ID: 32661823
[TBL] [Abstract][Full Text] [Related]
14. Antiprotease strategy in pancreatic cancer treatment: emergence from a preclinical study.
Brandi G; Tavolari S; Guarnieri T; Di Marco M; Paterini P; Macchini M; Di Girolamo S; Papi A; De Rosa F; Biasco G
Pancreas; 2014 Jan; 43(1):53-63. PubMed ID: 24201777
[TBL] [Abstract][Full Text] [Related]
15. Intrinsic chemoresistance to gemcitabine is associated with decreased expression of BNIP3 in pancreatic cancer.
Akada M; Crnogorac-Jurcevic T; Lattimore S; Mahon P; Lopes R; Sunamura M; Matsuno S; Lemoine NR
Clin Cancer Res; 2005 Apr; 11(8):3094-101. PubMed ID: 15837765
[TBL] [Abstract][Full Text] [Related]
16. Synergy of gemcitabine and lidamycin associated with NF-kappaB downregulation in pancreatic carcinoma cells.
Chen J; Wu SY; Ou-Yang ZG; Zhen YS
Acta Pharmacol Sin; 2008 May; 29(5):614-9. PubMed ID: 18430374
[TBL] [Abstract][Full Text] [Related]
17. TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3.
Hesler RA; Huang JJ; Starr MD; Treboschi VM; Bernanke AG; Nixon AB; McCall SJ; White RR; Blobe GC
Carcinogenesis; 2016 Nov; 37(11):1041-1051. PubMed ID: 27604902
[TBL] [Abstract][Full Text] [Related]
18. Elucidation of the relationship of BNIP3 expression to gemcitabine chemosensitivity and prognosis.
Ishida M; Sunamura M; Furukawa T; Akada M; Fujimura H; Shibuya E; Egawa S; Unno M; Horii A
World J Gastroenterol; 2007 Sep; 13(34):4593-7. PubMed ID: 17729412
[TBL] [Abstract][Full Text] [Related]
19. Rab14 overexpression regulates gemcitabine sensitivity through regulation of Bcl-2 and mitochondrial function in pancreatic cancer.
Ge J; Ge C
Virchows Arch; 2019 Jan; 474(1):59-69. PubMed ID: 30267303
[TBL] [Abstract][Full Text] [Related]
20. Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer.
Azorsa DO; Gonzales IM; Basu GD; Choudhary A; Arora S; Bisanz KM; Kiefer JA; Henderson MC; Trent JM; Von Hoff DD; Mousses S
J Transl Med; 2009 Jun; 7():43. PubMed ID: 19519883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]